Azamian Bobak R. sold $801K of TARS (indirect holdings)

Azamian Bobak R. (President/CEO and Board Chair) sold 10,000 indirectly-held shares of Tarsus Pharmaceuticals, Inc. (TARS) at $80.06 ($0.80M total) on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Azamian Bobak R.
Published Sep 3, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 11:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TARS
Bearish
medium confidence
Mentioned
$TARS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TARSBearishLow
01

Why it matters

Provides fresh data on insider holdings, useful for short‑term sentiment assessment.

02

Market read

First public disclosure of a CEO's share sale; modest relevance for traders monitoring insider activity.

03

What to watch

The remaining insider stake remains large, and the company has upcoming clinical milestones that could offset the sale.

Relevance 4/10Novelty 6/10Timing: post‑market 2026‑09‑02 filing

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$TARSBearishMedium confidence
Context

CEO sold 10,000 shares for $800,600 via a 10b5-1 plan, reducing his stake to 837,991 shares.

Expected impact

Possible modest dip of 1‑2% in the next trading session.

Evidence & confidence

Sale size is modest relative to float, but CEO involvement and open-market execution suggest a slight negative bias.

Market effects

Biopharma sector may see minor scrutiny of insider activity, but no broader impact.

U.S. market only; no regional ripple.

Limited to Tarsus shareholders; negligible global effect.

Counterpoint

The sale could be routine portfolio rebalancing under a 10b5‑1 plan, not a confidence signal.

Key entities

  • Azamian Bobak R.

    President/CEO and Board Chair of Tarsus Pharmaceuticals.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TARSHighAI 8/10

Tarsus (TARS) Q3 2026 Earnings Call Transcript

Tarsus (TARS) reported Q3 2026 net product sales of $194.6M for XDEMVY, up 64% YoY. The company raised full-year sales guidance to $715M-$730M. Key growth drivers include increased patient demand, broader ECP prescribing, and retreatment. Tarsus also discussed pipeline progress and acquisition integration.

$TARSMedAI 8/10

Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals (NASDAQ:TARS) increased its 2026 XDEMVY sales outlook to $715M-$730M, citing stronger demand and advertising returns. Q3 saw 20% sequential growth in high-prescribing eye care professionals. The company expects 2027 direct-to-consumer spending of $80M-$95M. Gross margin is projected at 93%, with SG&A and R&D expenses outlined. Pipeline updates include TP-03 launch in China and upcoming trials for TP-04, TP-05, and IRX-101.